The Center for Microbiome & Human Health is studying how the human microbiome impacts health and disease and developing microbiome-targeted therapeutics.
Our understanding of human physiology and disease susceptibility is dramatically changing. We now recognize that our bodies integrate the biology of our human cells and genome with the trillions of bacteria that live within and on us. In fact, a significant component of disease is derived from these microbial communities. Defining the processes and events responding to our microbiota offers new insights into disease processes, defines new relationships governing the natural history of human disease, and offers new approaches to treat and prevent diseaseMore About Us
Investigators in the Center for Microbiome & Human Health study various topics involving microbiomes in humans to develop novel therapeutics and approaches to disease management for the improvement of health and wellness of our patients.Learn More
Dr. Hazen identified the gbu gene cluster as a potential therapeutic target for diet-associated cardiovascular disease, and showed that dietary modifications may also help reduce risk.
Dr. Sharifi and collaborators identified choline, betaine and phenylacetylglutamine as nutrients and gut microbiome metabolites associated with increased risk for lethal prostate cancer, suggesting dietary interventions may help reduce disease risk.
Drs. Hazen and Zhu found that elevated levels of blood TMAO are associated with larger infarct volume and poorer functionality following injury in preclinical stroke models, offering the first evidence that the gut microbiome directly modulates stroke severity.